Your browser doesn't support javascript.
loading
Increased plasma levels of high mobility group box 1 protein in patients with bipolar disorder: A pilot study.
Marie-Claire, Cynthia; Courtin, Cindie; Curis, Emmanuel; Bouaziz-Amar, Elodie; Laplanche, Jean-Louis; Jacob, Aude; Etain, Bruno; Blanchard, Anne; Bellivier, Frank.
Afiliação
  • Marie-Claire C; INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Descartes, Université Paris Diderot, Université Sorbonne Paris Cité, Paris, France. Electronic address: cynthia.marie-claire@parisdescartes.fr.
  • Courtin C; INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Descartes, Université Paris Diderot, Université Sorbonne Paris Cité, Paris, France.
  • Curis E; INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Descartes, Université Paris Diderot, Université Sorbonne Paris Cité, Paris, France; AP-HP, GH Saint-Louis - Lariboisière - F. Widal, Département de biostatistiques et d'informatique médicales, Paris, France; Labora
  • Bouaziz-Amar E; INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Descartes, Université Paris Diderot, Université Sorbonne Paris Cité, Paris, France; GH Saint-Louis - Lariboisière - F. Widal, Département de Biochimie et Biologie moléculaire, Paris, France.
  • Laplanche JL; INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Descartes, Université Paris Diderot, Université Sorbonne Paris Cité, Paris, France; GH Saint-Louis - Lariboisière - F. Widal, Département de Biochimie et Biologie moléculaire, Paris, France.
  • Jacob A; INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Descartes, Université Paris Diderot, Université Sorbonne Paris Cité, Paris, France.
  • Etain B; INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Descartes, Université Paris Diderot, Université Sorbonne Paris Cité, Paris, France; AP-HP, GH Saint-Louis - Lariboisière - F. Widal, Pôle de Psychiatrie et de Médecine Addictologique, 75475 Paris Cedex 10, France;
  • Blanchard A; APHP, Hôpital Européen Georges Pompidou, INSERM CIC1418, Université Paris Descartes, 75015 Paris, France.
  • Bellivier F; INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Descartes, Université Paris Diderot, Université Sorbonne Paris Cité, Paris, France; AP-HP, GH Saint-Louis - Lariboisière - F. Widal, Pôle de Psychiatrie et de Médecine Addictologique, 75475 Paris Cedex 10, France;
J Neuroimmunol ; 334: 576993, 2019 09 15.
Article em En | MEDLINE | ID: mdl-31203140
High mobility group box 1 (HMGB1) is a pro-inflammatory cytokine that emerges as a promising peripheral marker of inflammation. HMGB1 and C-reactive protein levels were assessed in plasma of control subjects and remitted patients with bipolar disorder (BD). HMGB1 levels were significantly higher in patients with BD as compared to control subjects whereas C-reactive protein levels did not differ between the two groups. No significant effect of potential covariates was identified. The results of this pilot study suggest that HMGB1 might be a specific peripheral marker of inflammation in BD.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtorno Bipolar / Proteína HMGB1 Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtorno Bipolar / Proteína HMGB1 Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article